Bhubaneswar, Apr 26: In a significant milestone for women’s healthcare, India has launched its first domestically developed HPV test kits, marking a major step toward strengthening cervical cancer screening. These innovative kits are designed to enhance early detection, making screening more accessible and affordable for women across the country.

The landmark initiative was formally introduced by the Union Minister of State for Science and Technology, Jitendra Singh, at a special launch event. The development and validation of these test kits were part of a national program spearheaded by Grand Challenges India (GCI), Biotechnology Industry Research Assistance Council (BIRAC), and the Department of Biotechnology (DBT). This achievement reinforces India’s commitment to advancing healthcare self-reliance and medical innovation.

Two leading biotech firms, Mylab Discovery Solutions and Molbio Diagnostics, played a crucial role in creating these test kits. After extensive clinical evaluation at premier research centers, the kits were deemed reliable for precise screening. Among them, Mylab’s Pathodetect HR HPV Hi-Res DNA test stands out for its high-precision automated screening capabilities, ensuring accurate early cervical cancer detection, particularly in primary healthcare settings.

Cervical cancer remains a serious health concern for Indian women, with the country carrying a significant share of the global disease burden. Experts stress that improved HPV screening could drastically reduce mortality rates. The introduction of these indigenous test kits is expected to extend diagnostic access, especially to remote regions with limited laboratory infrastructure.

Healthcare officials anticipate that these test kits will soon be integrated into national healthcare programs, helping to reshape cervical cancer prevention strategies. The breakthrough is not only a step forward in public health but also a testament to India’s growing expertise in medical technology innovation.

With this advancement, India is moving closer to ensuring widespread cervical cancer screening, facilitating timely diagnosis, and improving patient care nationwide.